Why Structure Therapeutics Inc.’s (GPCR) Stock Is Up 6.14%
As of Wednesday, September 09, Structure Therapeutics Inc.’s GPCR share price has surged by 6.14%, which has investors questioning if this is right time to sell.Jenna Brashear
Stock Evaluator: Structure Therapeutics Inc. (GPCR)
Structure Therapeutics Inc. GPCR
$38.66
-0.89
-2.25%
September 11, 2026 4:00:00 PM
EST
Volume: 1,276,078
After Hours: $120.37
0.15
|
0.12%
November 10, 2021 7:59 PM
EST
Volume: 72,713
USD
NASD | DELAYED PRICE
| SECTOR | INDUSTRY |
| Health Care | Pharmaceuticals |
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral small molecule therapeutics to treat various chronic diseases with unmet medical needs in the United States. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, which is in two phase 2 clinical trials for the treatment of obesity, overweight, and related conditions. The company also develops ACCG-2671 and ACCG-3535, an oral small molecule amylin receptor agonist that is in phase1 clinical trial for the treatment of obesity; ANPA-0073, an oral small molecule APJ receptor agonist; and LTSE-2578, an antagonist that targets lysophosphatidic acid 1 receptor, a G-protein coupled receptors implicated in responses to tissue injury and pro-fibrotic processes, for the treatment of idiopathic pulmonary fibrosis. In addition, it develops programs, including glucose-dependent insulinotropic polypeptide receptor (GIPR) program, which identified multiple GIPR agonist, dual GLP-1R/GIPR agonist, and GIPR antagonist hits for small molecule GIPR modulation that has the potential to provide a treatment in obesity; and GCG program, which identified multiple GCG receptor (GCGR) agonist and dual GLP-1R/GCGR agonist hits for small molecule GCGR modulation. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.
Commentary & Analysis
Why Structure Therapeutics Inc.’s (GPCR) Stock Is Down 6.47%
As of Tuesday, September 08, Structure Therapeutics Inc.’s GPCR share price has dipped by 6.47%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Why Structure Therapeutics Inc.’s (GPCR) Stock Is Up 7.15%
As of Friday, August 21, Structure Therapeutics Inc.’s GPCR share price has surged by 7.15%, which has investors questioning if this is right time to sell.Jenna Brashear
Why Structure Therapeutics Inc.’s (GPCR) Stock Is Down 5.34%
As of Friday, July 31, Structure Therapeutics Inc.’s GPCR share price has dipped by 5.34%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Why Structure Therapeutics Inc.’s (GPCR) Stock Is Up 5.12%
As of Friday, July 17, Structure Therapeutics Inc.’s GPCR share price has surged by 5.12%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Financial Summary
| Share Statistics | GPCR | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $2,753.3 | $609.5 | 58% |
|
| Shares Out (Mil) | 72.7 | 43.4 | 56% |
|
| Institutional Ownership | 95.9% | 83.9% | 68% |
|
| Float (Mil) | 54.6 | 45.7 | 49% |
|
| Beta | -1.51 | 0.73 | 1% |
|
| Avg Daily Volume (000s) | 1,155 | 309 | 74% |
|
| Price Change (52-week) |
84.8% | 64.9% | 90% |
|
| Growth | GPCR | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 6.7% | na |
|
| Net Income (5yr) | (54.8%) | (1.6%) | 6% |
|
| EPS (5yr) | 20.9% | 15.1% | 70 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | 34.0% | (15.0%) | 88% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 10 | 10 | 8 | |
| Current EPS | ($0.261) | ($1.610) | ($2.113) | |
| Month Ago EPS | ($0.218) | ($1.548) | ($2.115) | |
| # Rev Up | 0 | 0 | 0 | |
| # Rev Down | 1 | 1 | 1 | |
| Three Months Ago EPS | ($0.161) | ($1.288) | ($1.902) | |
| Year/Year Chg | (82.1%) | (32.5%) | (36.2%) | |
| Financials | GPCR | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $317 | na |
|
| Net Income (TTM) (Mil) | ($215) | ($11) | 6% |
|
| EPS (TTM) | ($3.219) | ($0.700) | 11% |
|
| Operating Cash Flow (TTM) (Mil) | ($220) | ($7) | 3% |
|
| Net Cash Flow (TTM) (Mil) | $126 | $6 | 79% |
|
| Long-Term Debt (Q1) (Mil) | $4 | $6 | 23% |
|
| Enterprise Value (Q1) (Mil) | $2,173 | $525 | 50% |
|
| Valuation | GPCR | Industry Median |
Percentile (All Stocks) |
|
| P/B | 2.03 | 2.61 | 51% |
|
| P/E | na | 17.0 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | GPCR | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 68.8% | na |
|
| Net Margin | na | 0.8% | na |
|
| ROA | (19.2%) | (22.7%) | 21% |
|
| ROE | (20.2%) | (22.8%) | 23% |
|
| Liabilities to Assets | 5.0% | 33.1% | 2% |
|
| F-Score | 3 | 3 | 18% |
|
Structure Therapeutics Inc. did not pass any screens on 9/11/2026.
